Buoyed by hemophilia A gene therapy update, BioMarin switches to head-to-head study -- but shares slide on durability concerns
With its hemophilia A gene therapy poised to go through a pivotal program by the end of next year, BioMarin $BMRN set out to boost …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
